Literature DB >> 20367637

Epstein-Barr virus involvement in the pathogenesis of hydroa vacciniforme: an assessment of seven adult patients with long-term follow-up.

L Verneuil1, S Gouarin, F Comoz, F Agbalika, C Creveuil, M Varna, A Vabret, A Janin, D Leroy.   

Abstract

BACKGROUND: Hydroa vacciniforme (HV) is a chronic papulovesicular photodermatosis of childhood, with some cases persisting through adulthood. In children, the Epstein-Barr virus (EBV) has been detected in typical HV and in HV evolving into natural killer/T-cell lymphoma. No exploration of EBV infection has been performed in adult patients with HV with long-term follow-up.
OBJECTIVES: To assess EBV infection systematically in blood and in experimentally photoinduced lesions in adult patients with HV.
METHODS: Repeated tests for EBV DNA blood load using real-time polymerase chain reaction (PCR) and serological EBV tests were performed in seven adult patients with long-term follow-up. Skin samples from phototest-induced lesions and surrounding normal skin were studied using PCR, in situ hybridization and electron microscopy. ZEBRA protein was detected using immunostaining. Thirty-five patients with other photosensitive disorders were included as controls.
RESULTS: The EBV DNA blood load was strongly positive in the seven patients with HV and negative in 34 of 35 of the patients with other photosensitive disorders (P < 0.001). The levels were higher in photosensitive patients with HV than in patients with HV in clinical remission. Ultrastructurally, viral particles were detected in lymphocytes and also in keratinocytes in three experimentally phototest-induced lesions; they were not found in the surrounding normal skin. ZEBRA protein was also detected in phototest-induced lesions, but not in the surrounding normal skin.
CONCLUSION: EBV is involved in HV pathogenesis and persists in adult patients with HV. A positive EBV DNA load, specific to HV in the spectrum of photosensitive disorders, might be a useful biomarker in HV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367637     DOI: 10.1111/j.1365-2133.2010.09789.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  Antiviral treatment of a boy with EBV-associated hydroa vacciniforme.

Authors:  Anja Pahlow Mose; Niels Fisker; Ole Clemmensen; Anette Bygum
Journal:  BMJ Case Rep       Date:  2014-11-24

2.  Clonal expansion of Epstein-Barr virus (EBV)-infected γδ T cells in patients with chronic active EBV disease and hydroa vacciniforme-like eruptions.

Authors:  Taizo Wada; Akiko Toga; Yasuhisa Sakakibara; Tomoko Toma; Minoru Hasegawa; Kazuhiko Takehara; Tomonari Shigemura; Kazunaga Agematsu; Akihiro Yachie
Journal:  Int J Hematol       Date:  2012-08-12       Impact factor: 2.490

3.  Recurrent scarring papulovesicular lesions on sun-exposed skin in a 22-year-old man.

Authors:  Melissa A Levoska; Jeffrey I Cohen; Irini Manoli; Chyi-Chia Richard Lee; Steven S T Ching; Jessica Shand; Deborah Tamura; Kenneth H Kraemer; John J DiGiovanna
Journal:  J Am Acad Dermatol       Date:  2017-09-28       Impact factor: 11.527

4.  Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites.

Authors:  Jeffrey I Cohen; Irini Manoli; Kennichi Dowdell; Tammy A Krogmann; Deborah Tamura; Pierce Radecki; Wei Bu; Siu-Ping Turk; Kelly Liepshutz; Ronald L Hornung; Hiva Fassihi; Robert P Sarkany; Lori L Bonnycastle; Peter S Chines; Amy J Swift; Timothy G Myers; Melissa A Levoska; John J DiGiovanna; Francis S Collins; Kenneth H Kraemer; Stefania Pittaluga; Elaine S Jaffe
Journal:  Blood       Date:  2019-05-07       Impact factor: 25.476

Review 5.  Hydroa Vacciniforme and Hydroa Vacciniforme-Like Lymphoproliferative Disorder: A Spectrum of Disease Phenotypes Associated with Ultraviolet Irradiation and Chronic Epstein-Barr Virus Infection.

Authors:  Chien-Chin Chen; Kung-Chao Chang; L Jeffrey Medeiros; Julia Yu-Yun Lee
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.